



IRA L. SCHALL, CPA
DAVID C. ASHENFARB, CPA
MICHAEL L. SCHALL, CPA

THE GLAUCOMA FOUNDATION, INC.

Audited Financial Statements

December 31, 2021

307 Fifth Avenue, 15th Floor
New York, New York 10016
Tel: (212) 268-2800
www.schallandashenfARB.com

Independent Auditors' Report

To the Board of Directors of
The Glaucoma Foundation, Inc.

Opinion

We have audited the accompanying financial statements of The Glaucoma Foundation, Inc. (the "Foundation"), which comprise the statement of financial position as of December 31, 2021, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as of December 31, 2021, and the changes in net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one

resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users on the basis of these financial statements.


In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the Foundation's 2020 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated April 29, 2021. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2020, is consistent, in all material respects, with the audited financial statements from which it has been derived.


Schall & Ashenfarb
Certified Public Accountants, LLC

May 18, 2022

THE GLAUCOMA FOUNDATION, INC.
STATEMENT OF FINANCIAL POSITION
AT DECEMBER 31, 2021
(With comparative totals at December 31, 2020)

	<u>12/31/21</u>	<u>12/31/20*</u>
Assets		
Cash and cash equivalents	\$2,659,839	\$1,444,076
Pledges receivable	335,782	87,589
Prepaid expenses and other assets	14,101	15,717
Security deposit	27,796	27,796
Property and equipment, net (Note 3)	5,767	8,826
Investments held for board designated funds (Note 4)	1,344,691	840,253
Investments held for endowments (Note 5)	8,563,184	7,429,477
	<u> </u>	<u> </u>
Total assets	<u>\$12,951,160</u>	<u>\$9,853,734</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$47,222	\$35,480
Grants payable	543,187	319,370
Deferred rent	8,071	5,328
	<u> </u>	<u> </u>
Total liabilities	<u>598,480</u>	<u>360,178</u>
Net assets:		
Without donor restrictions:		
Operations	2,122,856	1,121,536
Board designated for medical research grants (Note 4)	939,599	554,161
Board designated for educational program reserve (Note 4)	405,092	286,092
Board designated for endowment (Note 5)	2,963,299	2,458,693
	<u> </u>	<u> </u>
Total net assets without donor restrictions	<u>6,430,846</u>	<u>4,420,482</u>
With donor restrictions:		
For future periods and programs (Note 6)	321,949	102,290
Donor restricted endowment (Note 5 and 6)	5,599,885	4,970,784
	<u> </u>	<u> </u>
Total net assets with donor restrictions	<u>5,921,834</u>	<u>5,073,074</u>
	<u> </u>	<u> </u>
Total net assets	<u>12,352,680</u>	<u>9,493,556</u>
	<u> </u>	<u> </u>
Total liabilities and net assets	<u>\$12,951,160</u>	<u>\$9,853,734</u>

* Reclassified for comparative purposes

The attached notes and auditors' report are an integral part of these financial statements.

THE GLAUCOMA FOUNDATION, INC.
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2021
(With comparative totals for the year ended December 31, 2020)

	With Donor Restrictions			Total 12/31/21	Total 12/31/20
	Without Donor Restrictions	Donor Restricted Support	Donor Restricted Endowment		
Support and revenue:					
Contributions	\$3,329,651	\$286,932		\$286,932	\$3,616,583
Interest income	610			0	610
Other income	60,000			0	60,000
Net assets released from restrictions	452,596	(67,273)	(\$385,323)	(452,596)	0
Total support and revenue	<u>3,842,857</u>	<u>219,659</u>	<u>(385,323)</u>	<u>(165,664)</u>	<u>3,677,193</u>
Expenses:					
Program services	1,921,409			0	1,921,409
Supporting services:					
Management and general	150,615			0	150,615
Fundraising	333,361			0	333,361
Total supporting services	<u>483,976</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>483,976</u>
Total expenses	<u>2,405,385</u>	<u>0</u>	<u>0</u>	<u>0</u>	<u>2,405,385</u>
Change in net assets from operating activities	<u>1,437,472</u>	<u>219,659</u>	<u>(385,323)</u>	<u>(165,664)</u>	<u>1,271,808</u>
Non-operating activities:					
Investment income (Note 5)	572,892		1,014,424	1,014,424	1,587,316
Total non-operating activities	<u>572,892</u>	<u>0</u>	<u>1,014,424</u>	<u>1,014,424</u>	<u>1,587,316</u>
Change in net assets	2,010,364	219,659	629,101	848,760	2,859,124
Net assets - beginning of year	<u>4,420,482</u>	<u>102,290</u>	<u>4,970,784</u>	<u>5,073,074</u>	<u>9,493,556</u>
Net assets - end of year	<u>\$6,430,846</u>	<u>\$321,949</u>	<u>\$5,599,885</u>	<u>\$5,921,834</u>	<u>\$12,352,680</u>

The attached notes and auditors' report are an integral part of these financial statements.

THE GLAUCOMA FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2021
(With comparative totals for the year ended December 31, 2020)

	Program Services			Supporting Services			Total Expenses 12/31/21	Total Expenses 12/31/20
	Education	Medical Research	Total Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries	\$309,981	\$252,029	\$562,010	\$67,948	\$112,126	\$180,074	\$742,084	\$707,493
Payroll taxes and benefits	65,478	53,235	118,713	14,348	23,685	38,033	156,746	147,649
Total salaries and related costs	<u>375,459</u>	<u>305,264</u>	<u>680,723</u>	<u>82,296</u>	<u>135,811</u>	<u>218,107</u>	<u>898,830</u>	<u>855,142</u>
Research grants		784,037	784,037			0	784,037	379,415
Think tank conference		101,745	101,745			0	101,745	595
Professional fees	30,000		30,000	33,800	30,000	63,800	93,800	98,573
Office expense	13,723	11,156	24,879	3,010	4,963	7,973	32,852	30,046
Direct mail	118,086		118,086		118,085	118,085	236,171	139,353
Occupancy	39,528	32,138	71,666	8,664	14,298	22,962	94,628	95,543
Postage and shipping	24,064		24,064	1,660		1,660	25,724	17,584
Conventions and travel	8,240		8,240			0	8,240	5,658
Insurance	3,544	2,881	6,425	777	1,282	2,059	8,484	4,686
Depreciation	1,279	1,039	2,318	279	462	741	3,059	2,743
Other	4,100		4,100	20,129	28,460	48,589	52,689	29,336
Community outreach	65,126		65,126			0	65,126	67,821
Total expenses	<u><u>\$683,149</u></u>	<u><u>\$1,238,260</u></u>	<u><u>\$1,921,409</u></u>	<u><u>\$150,615</u></u>	<u><u>\$333,361</u></u>	<u><u>\$483,976</u></u>	<u><u>\$2,405,385</u></u>	<u><u>\$1,726,495</u></u>

The attached notes and auditors' report are an integral part of these financial statements.

THE GLAUCOMA FOUNDATION, INC.
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2021
(With comparative totals for the year ended December 31, 2020)

	12/31/21	12/31/20*
Cash flows from operating activities:		
Change in net assets	\$2,859,124	\$1,512,891
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation	3,059	2,743
Net unrealized and realized gains on investments	(1,614,565)	(951,572)
Endowment contributions	0	(10,000)
Donated stock	(493,553)	(380,666)
Changes in assets and liabilities:		
Pledges receivable	(248,193)	(40,743)
Prepaid expenses and other assets	1,616	(686)
Accounts payable and accrued expenses	11,742	(31,529)
Grants payable	223,817	139,370
Deferred rent	2,743	5,328
Total adjustments	(2,113,334)	(1,267,755)
Net cash flows provided by operating activities	745,790	245,136
Cash flows from investing activities:		
Proceeds from sales of investments	2,922,465	1,914,704
Purchases of investments/reinvested income	(2,452,492)	(1,783,814)
Net cash flows provided by investing activities	469,973	130,890
Cash flows from financing activities:		
Endowment contributions	0	10,000
Net cash flows provided by financing activities	0	10,000
Net increase in cash and cash equivalents	1,215,763	386,026
Cash and cash equivalents - beginning of year	1,444,076	1,058,050
Cash and cash equivalents - end of year	\$2,659,839	\$1,444,076
Supplemental disclosures:		
Interest and taxes paid	\$0	\$0

* Reclassified for comparative purposes

The attached notes and auditors' report are an integral part of these financial statements.

THE GLAUCOMA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2021

Note 1 - Organization

The Glaucoma Foundation, Inc. (the "Foundation"), incorporated in New York State in 1984, was founded to stimulate and support basic and applied research in glaucoma, to gain and disseminate new information about the biological causes and treatment of glaucoma, and to identify and develop novel approaches to preserve visual function and reversal of blindness caused by glaucoma.

The Foundation is a not-for-profit organization and has been notified by the Internal Revenue Service that it is exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code and has not been determined to be a private foundation as defined in Section 509(a).

Note 2 - Summary of Significant Accounting Policies

a. Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting which is the process of recognizing revenue and expenses when earned or incurred rather than received or paid.

b. Basis of Presentation

The Foundation reports information regarding their financial position and activities according to the following classes of net assets:

- *Net Assets Without Donor Restrictions* – represents those resources for which there are no restrictions by donors as to their use. The board has designated funds to be used for the following specific purposes:
 - Medical research grants
 - Educational programs
 - Endowment funds

(See Note 4 and 5 for details.)

As the funds are internally designated, they are reflected on the financial statements as without donor restrictions.

- *Net Assets With Donor Restrictions* – represents those resources, the uses of which have been restricted by donors to specific purposes or the passage of time and/or must remain intact, in perpetuity. The release from restrictions results from the satisfaction of the restricted purposes specified by the donor.

c. Revenue Recognition

The Foundation follows the requirements of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 958-605 for recording contributions, which are recognized at the earlier of when cash is received or at the time a pledge becomes unconditional in nature. Contributions are recorded in the net asset classes referred to above depending on the existence and/or nature of any donor-imposed restriction. When a restriction expires, that is, when a stipulated time restriction ends, or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions. If donor restricted contributions are satisfied in the same period they were received, they are classified as without donor restrictions.

Contributions may be subject to conditions which are defined as both a barrier to entitlement and a right of return of payments or release from obligations and are recognized as income once the conditions have been substantially met.

Pledges that are expected to be received in less than one year are recorded at net realizable value. Those that are due in greater than one year are recorded at fair value, which is calculated using risk-adjusted present value techniques if deemed material. Long-term pledges are considered time-restricted until the period they are due, at which time they will be released from restriction and counted towards operations. All pledges receivable as of December 31, 2021 are expected to be received within one year.

Management reviews receivables for collectability based on various factors such as historical trends and subsequent collections. Based on this review, management has deemed that no allowance for doubtful accounts is necessary for the periods ended December 31, 2021 and 2020.

d. Cash and Cash Equivalents

The Foundation considers cash held in checking accounts and money market funds with a maturity of three months or less to be cash and cash equivalents.

e. Concentration of Credit Risk

Financial instruments which potentially subject the Foundation to concentration of credit risk, consist of cash accounts, which are placed with financial institutions that management deems to be creditworthy. At times and at year end, balances may exceed federally insured limits. While at year end the Foundation had uninsured balances, management feels they have little risk and have not experienced any losses due to bank failure.

f. Fair Value Measurement

Fair value refers to the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. Accounting standards have established a fair value hierarchy giving the highest priority to quoted market prices in active markets and the lowest priority to unobservable data. The fair value hierarchy is categorized into three levels based on the inputs as follows:

- Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Foundation has the ability to access.
- Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are not observable, either directly or indirectly.
- Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

g. Property and Equipment

Purchases of furniture, equipment, and other fixed assets that have a useful life of greater than one year and exceed predetermined amounts are capitalized at cost or, if donated, at their fair value at the date of the gift. Property and equipment are depreciated using the straight-line method over the estimated useful life of the asset.

h. Deferred Rent

Rent expense is recognized evenly over the life of the lease using the straight-line method. In the earlier years of the lease, as rent expense exceeds amounts paid, a deferred rent liability is created. In later years of the lease, as payments exceed the amount of expense recognized, deferred rent will be reduced until it is zero at the end of the lease.

i. Contributed Services

Donated services are recognized in circumstances when they create or enhance non-financial assets or where those services require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided in-kind.

Board members and other individuals volunteer their time and perform a variety of services that assist the Foundation. These services have not been recorded in the financial statements because they do not meet the criteria for recognition as outlined above.

j. Management Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

k. Functional Allocation of Expenses

The costs of providing various programs and other activities have been summarized on a functional basis in the financial statements. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

The following costs are allocated using time and effort as a basis:

- Salaries
- Payroll taxes and benefits
- Office expense
- Occupancy
- Insurance
- Depreciation

Direct mail is allocated evenly between program and fundraising due to the content distributed in mailings. All other expenses have been charged directly to the applicable program or supporting services.

l. Prior Year Comparative Financial Information

The financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Foundation's financial statements for the year ended December 31, 2020, from which the summarized information was derived.

m. Accounting for Uncertainty of Income Taxes

The Foundation does not believe its financial statements include any material uncertain tax positions. Tax filings for periods ending December 31, 2018 and later are subject to examination by applicable taxing authorities.

n. New Accounting Pronouncements

FASB issued Accounting Standards Update ("ASU") No. 2020-07, *Presentation and Disclosure by Not-for-Profit Entities for Contributed Nonfinancial Assets*, which becomes effective for the December 31, 2022 year. This ASU focuses on improving transparency in the reporting of contributed nonfinancial assets and requires a separate line-item presentation on the statement of activities and additional disclosures.

FASB issued ASU No. 2016-02, *Leases*. The ASU which becomes effective for the December 31, 2022 year, requires the full obligation of long-term leases to be recorded as a liability with a corresponding "right to use asset" on the statement of financial position.

The Foundation is in the process of evaluating the impact these standards will have on future financial statements.

Note 3 - Property and Equipment

Property and equipment consist of the following:

	<u>12/31/21</u>	<u>12/31/20</u>
Computer software (5 years)	\$37,027	\$37,027
Furniture and equipment (5 years)	<u>59,485</u>	<u>59,485</u>
	96,512	96,512
Less: accumulated depreciation	<u>(90,745)</u>	<u>(87,686)</u>
Total property and equipment, net	<u>\$5,767</u>	<u>\$8,826</u>

Note 4 - Investments Held for Board Designated Funds

The following summarizes assets that are held for board designations:

	<u>December 31, 2021</u>		
	<u>Medical Research</u>	<u>Education</u>	<u>Total</u>
Net assets, beginning of year	\$554,161	\$286,092	\$840,253
Contributions	0	50,000	50,000
Interest and dividend income	115	4,646	4,761
Net gain on investments	0	64,354	64,354
Appropriated from endowment	<u>385,323</u>	<u>0</u>	<u>385,323</u>
Total	<u>\$939,599</u>	<u>\$405,092</u>	<u>\$1,344,691</u>

	<u>December 31, 2020</u>		
	<u>Medical Research</u>	<u>Education</u>	<u>Total</u>
Net assets, beginning of year	\$387,167	\$0	\$387,167
Contributions	0	250,000	250,000
Interest and dividend income	914	3,820	4,734
Net gain on investments	0	32,272	32,272
Appropriation for spending	<u>166,080</u>	<u>0</u>	<u>166,080</u>
Total	<u>\$554,161</u>	<u>\$286,092</u>	<u>\$840,253</u>

Investments held for board designated funds consist of:

	<u>December 31, 2021</u>		
	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
Equities – U.S. diversified	\$337,062	\$0	\$337,062
Short term treasuries and money market account	942,656	0	942,656
U.S. Treasury securities	0	24,995	24,995
U.S. Corporate bonds	<u>0</u>	<u>39,978</u>	<u>39,978</u>
Total	<u>\$1,279,718</u>	<u>\$64,973</u>	<u>\$1,344,691</u>

	<u>December 31, 2020</u>		
	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
Equities – U.S. diversified	\$221,894	\$0	\$221,894
Short term treasuries and money market account	562,397	0	562,397
U.S. Treasury securities	0	19,996	19,996
U.S. Corporate bonds	<u>0</u>	<u>35,966</u>	<u>35,966</u>
Total	<u>\$784,291</u>	<u>\$55,962</u>	<u>\$840,253</u>

Note 5 - Investments Held for Endowments

The Foundation's endowment includes donor restricted individual and corporate funds to be held indefinitely and board designated funds for the growth of the endowment and research grants. The income from the donor restricted investments can be used to support the Foundation's research reserve for medical research grants.

Interpretation of Relevant Law

The Foundation follows New York State adopted New York Prudent Management of Institutional Funds Act ("NYPMIFA"), which the Foundation has interpreted as requiring certain amounts to be retained in perpetuity. Absent explicit donor stipulations to the contrary, the Foundation will preserve the fair value of the original gift as of the gift date of all donor-restricted endowment funds. However, under certain circumstances, the Foundation has the right to appropriate for expenditure the fair value of the original gift in a manner consistent with the standard of prudence specifically prescribed by NYPMIFA.

As a result of this interpretation, the Foundation classifies as endowment corpus (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the donor's intention.

When endowment funds have earnings in excess of amounts that need to be retained as part of the corpus, their earnings are restricted until the board appropriates for expenditure, therefore, they have been classified in the class of net assets with donor restrictions.

Spending Policies

In accordance with NYPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the Foundation and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effect of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the Foundation
- (7) The investment policies of the Foundation
- (8) Where appropriate and circumstances would otherwise warrant alternatives to expenditure of the endowment fund, giving due consideration to the effect that such alternatives may have on the Foundation

The Foundation's spending policy allows for semi-annual distributions of 2.5% of the previous year's balance to fund Glaucoma research if the total market valuation of the endowment assets is above \$5,000,000.

Changes in endowment net assets were as follows:

	December 31, 2021				
	Board	<u>Donor Restricted Endowment</u>			<u>Total</u>
	Designated <u>Endowment</u>	Endowment <u>Corpus</u>	Endowment <u>Earnings</u>	<u>Total</u>	
Endowment net assets, Beginning of year	\$2,458,693	\$1,550,187	\$3,420,597	\$4,970,784	\$7,429,477
Contributions	493,553	0	0	0	493,553
Appropriations (for medical research)	(492,839)	0	(385,323)	(385,323)	(878,162)
Interest and dividend income	30,923	0	62,256	62,256	93,179
Net gain on investments	<u>472,969</u>	<u>0</u>	<u>952,168</u>	<u>952,168</u>	<u>1,425,137</u>
Endowment net assets, end of year	<u>\$2,963,299</u>	<u>\$1,550,187</u>	<u>\$4,049,698</u>	<u>\$5,599,885</u>	<u>\$8,563,184</u>

	December 31, 2020				
	Board	<u>Donor Restricted Endowment</u>			<u>Total</u>
	Designated <u>Endowment</u>	Endowment <u>Corpus</u>	Endowment <u>Earnings</u>	<u>Total</u>	
Endowment net assets, Beginning of year	\$2,174,572	\$1,540,187	\$2,966,456	\$4,506,643	\$6,681,215
Contributions	370,666	10,000	0	10,000	380,666
Appropriations	(384,457)	0	(166,080)	(166,080)	(550,537)
Interest and dividend income	33,333	0	68,804	68,804	102,137
Net gain on investments	<u>264,579</u>	<u>0</u>	<u>551,417</u>	<u>551,417</u>	<u>815,996</u>
Endowment net assets, end of year	<u>\$2,458,693</u>	<u>\$1,550,187</u>	<u>\$3,420,597</u>	<u>\$4,970,784</u>	<u>\$7,429,477</u>

Funds with Deficiencies

From time to time, the fair market value of assets associated with the individual donor-restricted endowment funds may fall below the level that the donor or NYPMIFA requires the Foundation to retain as a fund of perpetual duration. There were no such deficiencies as of December 31, 2021 and 2020.

Investments held for endowment consist of:

	<u>December 31, 2021</u>		
	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
Equities – U.S. diversified	\$7,941,472	\$0	\$7,941,472
Short term treasuries and money market account	170,863	0	170,863
U.S. Treasury securities	0	184,949	184,949
U.S. Corporate bonds	<u>0</u>	<u>265,900</u>	<u>265,900</u>
Total	<u>\$8,112,335</u>	<u>\$450,849</u>	<u>\$8,563,184</u>

	<u>December 31, 2020</u>		
	<u>Level 1</u>	<u>Level 2</u>	<u>Total</u>
Equities – U.S. diversified	\$6,846,735	\$0	\$6,846,735
Short term treasuries and money market account	289,532	0	289,532
U.S. Treasury securities	0	149,993	149,993
U.S. Corporate bonds	<u>0</u>	<u>143,217</u>	<u>143,217</u>
Total	<u>\$7,136,267</u>	<u>\$293,210</u>	<u>\$7,429,477</u>

Level 1 securities are valued at the closing price reported on the active market they are traded on. Level 2 securities are valued using observable market inputs for securities that are similar to those owned. This method produces a fair value calculation that may not be indicative of net realizable value or reflective of future values. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurements.

The following summarizes investment income:

	<u>12/31/21</u>	<u>12/31/20</u>
Interest and dividend income	\$97,825	\$105,957
Investment fees	(125,074)	(103,304)
Realized gain on sales of investments	522,096	46,195
Unrealized gain	<u>1,092,469</u>	<u>905,377</u>
Total	<u>\$1,587,316</u>	<u>\$954,225</u>

Note 6 - Net Assets With Donor Restrictions

The following summarizes the nature of net assets with donor restrictions:

	<u>12/31/21</u>	<u>12/31/20</u>
Endowment:		
Corpus:		
Joe LaMotta research endowment	\$1,530,187	\$1,530,187
DM Mendelshon endowment	<u>20,000</u>	<u>20,000</u>
Total corpus	<u>1,550,187</u>	<u>1,550,187</u>
Endowment earnings:		
Joe LaMotta research endowment	4,048,679	3,419,581
DM Mendelshon endowment	<u>1,019</u>	<u>1,016</u>
Total endowment earnings	<u>4,049,698</u>	<u>3,420,597</u>
Total endowment (See Note 5)	5,599,885	4,970,784
Program restrictions	196,949	102,290
Time restrictions	<u>125,000</u>	<u>0</u>
Total net assets with donor restrictions	<u>\$5,921,834</u>	<u>\$5,073,074</u>

The following summarizes net assets released from restrictions:

	<u>12/31/21</u>	<u>12/31/20</u>
Joe LaMotta research endowment -		
Appropriations	\$385,323	\$166,080
Program restrictions	<u>67,273</u>	<u>29,721</u>
Total released from restriction	<u>\$452,596</u>	<u>\$195,801</u>

Note 7 - Availability and Liquidity

The following reflects the Foundation's financial assets at December 31, 2021 that are available to meet cash needs for general expenditures within one year:

Financial assets at year-end:		
Cash and cash equivalents		\$2,659,839
Pledges receivable		335,782
Investments held for board designated funds		1,344,691
Investments held for endowments		<u>8,563,184</u>
Total financial assets		\$12,903,496
Add amount appropriated for next year's spending		214,000
Less amounts not available for general expenditures:		
Board designated for medical research grants		(939,599)
Board designated for educational program reserve		(405,092)
Board designated for endowment		(2,963,299)
Donor restricted endowment corpus		(1,550,187)
Donor restricted endowment earnings		<u>(4,049,698)</u>
Total amounts not available for general expenditures		<u>(9,907,875)</u>
Financial assets available to meet cash needs		
for general expenditures within one year		<u>\$3,209,621</u>

The Foundation's endowment funds are held for long term purposes and consist of donor-restricted endowments and a board designated endowment. Therefore, these assets are not considered available for general expenditures.

Note 8 - Retirement Plan

The Foundation offers a SIMPLE IRA retirement plan, which allows all employees who earn at least \$5,000 during the preceding calendar year and expect to earn \$5,000 in the current calendar year, to participate. Employees may elect to defer a portion of their salary and contribute to this plan up to statutory amounts on a monthly basis. The employer will contribute a matching contribution equal to the employee's deferrals, limited to 3% of the employee's compensation for the calendar year. Contributions made by the Foundation to the plan totaled \$22,183 and \$20,974 during the years ended December 31, 2021 and 2020, respectively.

Note 9 - Commitments

The Foundation occupies office space under a non-cancelable lease which expires on December 31, 2024.

Future minimum payments are as follows:

Year ending:	December 31, 2022	\$91,423
	December 31, 2023	94,166
	December 31, 2024	<u>96,990</u>
Total		<u>\$282,579</u>

Note 10 - Subsequent Events

Subsequent events have been evaluated through May 18, 2022, the date the financial statements were available to be issued. Adjustments and disclosures have been made for all subsequent events that have occurred.

Note 11 - Other Matters

On January 30, 2020, the World Health Organization declared the coronavirus outbreak a "Public Health Emergency of International Concern" and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area, in which the Foundation operates. As of the date of these financial statements, many of the travel restrictions and stay at home orders have been lifted; however, supply chains remain impacted. Management continues to monitor the outbreak; however, as of the date of these financial statements, the potential impact cannot be quantified.